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The letter by Hisato Takagi provides further interesting data
on the role of endoluminal superficial femoral artery (SFA) inter-
ventions. Their analysis of the four randomized trials that are
presently available in the literature confirms that percutaneous
angioplasty alone remains the primary treatment for SFA disease,
with stent placement being reserved for technical and procedure-
related complications. The recent data on drug-eluting stents,
although suggesting a marginal benefit, have shown that changes
in stent technology have not altered the balance between primary
PTA and primary stenting. The analysis by Takagi et al is weakened
by virtue of the fact that they were unable to categorize treated
vessels by TransAtlantic Inter-Society Consensus (TASC) classifi-
cation. This would significantly aid those pursuing SFA interven-
tions. Our own data suggested that TASC A and B lesions per-
formed satisfactorily to PTA, with secondary stenting as needed,
and that C and D lesions do not perform as well as conventional
bypass. We still pursue the belief that primary PTA for SFA disease
remains the treatment of choice, with stents being used selectively.
Mark G. Davies, MD, PhD
Scott M. Suroweic, MD




Regarding “Perioperative beta-blockade (POBBLE)
for patients undergoing infrarenal vascular surgery:
results of a randomized double-blind controlled trial”
We read with great interest the recent article by the POBBLE
trial investigators (J Vasc Surg 2005;41:602-609). Beta blockers
have a beneficial effect in patients with ischemic heart disease and
improve long-term outcome. Hence, it is not surprising that
-blockers are recommended in patients with or at risk for coro-
nary artery disease scheduled for noncardiac surgery, because car-
diac events are the major cause of perioperative morbidity and
mortality.1
The investigators reported the outcome of 97 low-risk pa-
tients—thosewith a history of ischemic heart disease were excluded—
who underwent open infrarenal vascular surgery. Patients were
randomized for metoprolol, started 1 day before surgery (n 53),
or placebo (n  44). The authors concluded that -blockers did
not improve 30-day cardiovascular outcome. However, the timing
and dosing of -blockers may have influenced their results.
The mechanisms by which -blockers exert their cardiopro-
tective effect are multifactorial. Beta blockers reduce heart rate and
contractility and, subsequently, myocardial oxygen demand; in-
duce a shift from free fatty acids toward glucose as the main cardiac
energy substrate, thus resulting in an improved energy efficiency
and outcome2; possess an antiarrhythmic effect and anti-renin/
angiotensin properties3; and have anti-inflammatory qualities.4
The effects on heart rate, contractility, and energy substrate shift
occur almost instantly. However, the effect on inflammatory re-
sponse may be observed only after a prolonged period of -blocker
use.4 In a randomized study of 200 surgical patients at risk for
coronary artery disease, Mangano et al5 found no difference in the
incidence of perioperative cardiac events among -blocker users,
but there was a reduced incidence of late fatal cardiac events. The
benefits of -blocker use were not immediately apparent but
evolved over the first 6 to 8 months after initiation of -blocker
therapy. It is possible that in the current trial, in an equally low-risk
population and with similar timing of -blocker therapy (ie, 1 day
before surgery), not all pleiotropic effects of -blockers were
achieved: the benefits of -blockers would then become evident
only weeks after surgery.
Another point of concern in this current trial is the lack of dose
adjustments for heart rate control in patients taking metoprolol. In
a study by Raby et al6 of 150 patients, ischemia was observed
before vascular surgery by using ambulatory electrocardiographic
monitoring in 26 patients. The heart rate at which ischemia oc-
curred was noted (ischemic threshold), and these patients were
randomized to either tight heart rate control (ie, 20% less than the
ischemic threshold but 60 bpm) or normal, nonadjusted
-blocker therapy. In 13 patients with heart rates below the
ischemic threshold, 1 (7.7%) had postoperative ischemia, vs 12
(92%) of 13 patients with less tight control. To interpret this study,
information regarding heart rate control in the perioperative phase
(not only at 4 hours after the first dose and 7 days after surgery) is
mandatory.
Future studies evaluating the effect of perioperative -blockers
in noncardiac surgery should focus not only on the prescription of
-blockers, but also on the optimal dosing and timing.
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